Axonics Announces Definitive Agreement to be Acquired by Boston Scientific
Axonics, Inc. (Nasdaq: AXNX) today announced that it has entered into a definitive agreement to be acquired by Boston Scientific Corporation (NYSE: BSX) for $71 in cash per share, representing an equity value of approximately $3.7 billion.
- Axonics, Inc. (Nasdaq: AXNX) today announced that it has entered into a definitive agreement to be acquired by Boston Scientific Corporation (NYSE: BSX) for $71 in cash per share, representing an equity value of approximately $3.7 billion.
- Axonics brings a complementary product portfolio to the Boston Scientific Urology business.
- Upon completion of the transaction, Axonics will become a wholly owned subsidiary of Boston Scientific.
- J.P. Morgan Securities LLC is serving as financial advisor and K&L Gates LLP is serving as legal counsel to Axonics.